Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds

Anthony Cole Gallegos; Michael James Davis; Catherine N. Tchanque-Fossuo; Kaitlyn West; Angela Eisentrout-Melton; Thomas R. Peavy; Roy W. Dixon; Roma P. Patel; Sara Evona Dahle; Roslyn Rivkah Isseroff

doi:10.1089/wound.2019.0970

Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds

Anthony Cole Gallegos, Michael James Davis, Catherine N. Tchanque-Fossuo, Kaitlyn West, Angela Eisentrout-Melton, Thomas R. Peavy, Roy W. Dixon, Roma P. Patel, Sara Evona Dahle, Roslyn Rivkah Isseroff

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucoma patients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds, providing insight as to the safety of this emerging off-label treatment. Conclusion: The topical application of timolol for chronic wounds shares the same safety profile as the widely used application of ocular administration for glaucoma.

Original language	English (US)
Pages (from-to)	538-545
Number of pages	8
Journal	Advances in Wound Care
Volume	8
Issue number	11
DOIs	https://doi.org/10.1089/wound.2019.0970
State	Published - Nov 1 2019
Externally published	Yes

Keywords

absorption
adrenergic receptor
catecholamine
chronic wounds
glaucoma
timolol

ASJC Scopus subject areas

Emergency Medicine
Critical Care and Intensive Care Medicine

Access to Document

10.1089/wound.2019.0970

Cite this

Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds. / Gallegos, Anthony Cole; Davis, Michael James; Tchanque-Fossuo, Catherine N.; West, Kaitlyn; Eisentrout-Melton, Angela; Peavy, Thomas R.; Dixon, Roy W.; Patel, Roma P.; Dahle, Sara Evona; Isseroff, Roslyn Rivkah.

In: Advances in Wound Care, Vol. 8, No. 11, 01.11.2019, p. 538-545.

Research output: Contribution to journal › Article › peer-review

Gallegos, Anthony Cole ; Davis, Michael James ; Tchanque-Fossuo, Catherine N. ; West, Kaitlyn ; Eisentrout-Melton, Angela ; Peavy, Thomas R. ; Dixon, Roy W. ; Patel, Roma P. ; Dahle, Sara Evona ; Isseroff, Roslyn Rivkah. / Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds. In: Advances in Wound Care. 2019 ; Vol. 8, No. 11. pp. 538-545.

@article{5d76169b9d5c45958cc44a9350e94dc2,

title = "Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds",

abstract = "There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucoma patients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds, providing insight as to the safety of this emerging off-label treatment. Conclusion: The topical application of timolol for chronic wounds shares the same safety profile as the widely used application of ocular administration for glaucoma.",

keywords = "absorption, adrenergic receptor, catecholamine, chronic wounds, glaucoma, timolol",

author = "Gallegos, {Anthony Cole} and Davis, {Michael James} and Tchanque-Fossuo, {Catherine N.} and Kaitlyn West and Angela Eisentrout-Melton and Peavy, {Thomas R.} and Dixon, {Roy W.} and Patel, {Roma P.} and Dahle, {Sara Evona} and Isseroff, {Roslyn Rivkah}",

year = "2019",

month = nov,

day = "1",

doi = "10.1089/wound.2019.0970",

language = "English (US)",

volume = "8",

pages = "538--545",

journal = "Advances in Wound Care",

issn = "2162-1918",

publisher = "Mary Ann Liebert Inc.",

number = "11",

}

TY - JOUR

T1 - Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds

AU - Gallegos, Anthony Cole

AU - Davis, Michael James

AU - Tchanque-Fossuo, Catherine N.

AU - West, Kaitlyn

AU - Eisentrout-Melton, Angela

AU - Peavy, Thomas R.

AU - Dixon, Roy W.

AU - Patel, Roma P.

AU - Dahle, Sara Evona

AU - Isseroff, Roslyn Rivkah

PY - 2019/11/1

Y1 - 2019/11/1

N2 - There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucoma patients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds, providing insight as to the safety of this emerging off-label treatment. Conclusion: The topical application of timolol for chronic wounds shares the same safety profile as the widely used application of ocular administration for glaucoma.

AB - There are no safety or absorption studies to guide topical timolol therapy for treatment of chronic wounds. This study was undertaken to address this gap. Approach: A prospective, observational, cross-sectional comparative study of timolol plasma levels in patients after topical administration to a chronic wound, compared with levels in patients after timolol ocular administration for the indication of glaucoma. Results: There was no statistically significant difference in the average plasma level of timolol in wound as compared with glaucoma patients. No bradycardia or wheezing was observed after administration. Innovation: We determined the single time point concentration of timolol in plasma 1 h after application of timolol 0.5% gel-forming solution to debrided chronic wounds, providing insight as to the safety of this emerging off-label treatment. Conclusion: The topical application of timolol for chronic wounds shares the same safety profile as the widely used application of ocular administration for glaucoma.

KW - absorption

KW - adrenergic receptor

KW - catecholamine

KW - chronic wounds

KW - glaucoma

KW - timolol

UR - http://www.scopus.com/inward/record.url?scp=85073879406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073879406&partnerID=8YFLogxK

U2 - 10.1089/wound.2019.0970

DO - 10.1089/wound.2019.0970

M3 - Article

AN - SCOPUS:85073879406

VL - 8

SP - 538

EP - 545

JO - Advances in Wound Care

JF - Advances in Wound Care

SN - 2162-1918

IS - 11

ER -

Absorption and Safety of Topically Applied Timolol for Treatment of Chronic Cutaneous Wounds

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this